WTR Healthcare Happenings
By Joe Brunetto
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Joe Brunetto
Category: Investing
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 57
Description
WTR Healthcare Happenings is a weekly conversation with healthcare executives, medical experts, and investors on recent clinical data or industry-driving events in healthcare.
| Episode | Date |
|---|---|
|
Jupiter Neurosciences (JUNS): Jotrol’s Bioavailability Breakthrough and the Key Parkinson’s Phase 2A Readout
|
Jun 17, 2026 |
|
NurExone Biologic (NRX): The Inhibitor of the Inhibitor: How Nurexone's ExoPTEN Is Designed to Restart Nerve Regeneration
|
Jun 11, 2026 |
|
PharmAla Biotech (MDMA): Two Transactions, One Strategy: Unlocking Pipeline Value Through Structured Partnerships
|
Jun 03, 2026 |
|
Solvonis Therapeutics (SVNS): CSO Professor David Nutt on Solvonis' Approach to Resetting the Addicted Brain
|
May 27, 2026 |
|
Solvonis Therapeutics (SVNS): Rewriting the Standard of Care for Severe Alcohol Use Disorder
|
May 20, 2026 |
|
PetVivo Holdings (PETV): The Trifecta: Regenerative Science, AI-Enabled Vet Care, and Human Translation
|
May 19, 2026 |
|
SBC Medical (SBC): Scaling Aesthetics, Longevity, and Global Growth
|
May 13, 2026 |
|
ExoZymes (EXOZ): Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free Biomanufacturing
|
May 06, 2026 |
|
Hidden Gems - Unlocking Value in Biotech's Most Overlooked Stocks
|
May 01, 2026 |
|
Vivos Therapeutics (VVOS): 2025 Results and Path to Cash Flow Breakeven by End-2026
|
Apr 28, 2026 |
|
Trump's Psychedelic Medicine Executive Order: What It Means for Patients and Investors
|
Apr 21, 2026 |
|
WTR Insights Conference Preview: Nurexone's Nerve Regeneration & Anixa's Cancer Immunotherapy in Focus
|
Apr 10, 2026 |
|
Circular Genomics: Cracking the Brain Code with Circular RNA
|
Apr 01, 2026 |
|
Unmasking the Treatment Landscape for Obstructive Sleep Apnea (OSA)
|
Mar 27, 2026 |
|
Psychedelics at a Turning Point: The Trials That Could Change Mental Health Treatment
|
Mar 20, 2026 |
|
Anixa Biosciences (ANIX): CEO Dr. Amit Kumar on Why 2026 Is Poised to Be a Defining Year
|
Mar 12, 2026 |
|
Omniscient Neurotechnology: Scaling up Clinical Connectomics SaaS Strategy and Neurotech Vision
|
Mar 04, 2026 |
|
Decoy Therapeutics (DCOY): CEO Rick Pierce on the Company’s Groundbreaking Approach to Drug Development in the AI/ML Era
|
Feb 25, 2026 |
|
NurExone Biologic (OTCQB: NRXBF / TSXV: NRX): CEO Dr. Lior Shaltiel on How the Company Stands Out as an Early‑Clinical‑Stage Biotech
|
Feb 12, 2026 |
|
Taking Aim at Norovirus; Cocrystal Pharma's (COCP) Clinical Antiviral Opportunity
|
Feb 04, 2026 |
|
How Entropy Neurodynamics (ASX: ENP) Is Shaping Psychedelic‑Assisted Therapy: Psilocin Programs, Binge Eating Disorder, and EEG Biomarker
|
Jan 28, 2026 |
|
Anixa' (ANIX) T-Cell Innovations Demonstrate Early Breakthrough Potential in Solid Tumors
|
Jan 22, 2026 |
|
The lure of the NASDAQ for Biotechs
|
Jan 16, 2026 |
|
Redefining Cancer Treatment: Calidi Biotherapeutics’ Approach to Enable Systemic Oncolytic Virotherapy for Metastatic Disease
|
Jan 08, 2026 |
|
Co-Diagnostic' Technology to Deliver Accessible, High-Fidelity Gold Standard PCR Testing Like No Other
|
Dec 23, 2025 |
|
CEO Jagi Gill on How Apyron' Innovative Neurostimulation Solution Breaks the Chronic Pain Barrier
|
Dec 19, 2025 |
|
RenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancers
|
Dec 18, 2025 |
|
Vivos Therapeutics’ Mission to Transform Sleep Treatment
|
Dec 10, 2025 |
|
GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders
|
Dec 03, 2025 |
|
Ainos' Director of Corporate Development Jack Lu Discusses the AI Nose Platform' continuing 2025 momentum and Looks Ahead into 2026
|
Nov 20, 2025 |
|
The Psychedelic Investment Environment: A New Era of Optimism
|
Nov 14, 2025 |
|
Solvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation
|
Nov 07, 2025 |
|
Reversing the Irreversible: NurExone Biologic’s (NRXBF) Regenerative Exosome Therapy for Spinal Cord and Nerve Injuries
|
Oct 30, 2025 |
|
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
|
Oct 22, 2025 |
|
CEO Dr. Amit Kumar Discusses Anixa Biosciences' Innovative Approach to Help T-Cells Address Solid Tumors
|
Oct 15, 2025 |
|
Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market
|
Oct 08, 2025 |
|
Revolutionizing Stroke Prevention: InspireMD’s CGuard® Prime and the Future of Carotid Stenting
|
Sep 24, 2025 |
|
Transforming Global Healthcare Access: Doc.com’s Mission for Free Basic Telemedicine
|
Sep 18, 2025 |
|
Psychedelics Sector Deals 2025: AbbVie/Gilgamesh Impact and Market Outlook
|
Sep 03, 2025 |
|
Ludwig's Dr. Marvin Hausman on Why Its Cheek-Swabbing mRNA Technology Platform Promises to be a Revolutionary Diagnostic Tool
|
Aug 19, 2025 |
|
CEO Brent Lucas on Why Envoy Medical's Device Technology is Currently the Only Change Agent in Hearing Health
|
Aug 13, 2025 |
|
Ainos' Director of Corporate Development Jack Lu on Why SmellTech Platform AI Nose is a Foundational Product in AI
|
Jul 22, 2025 |
|
Lisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic Cancer
|
Jul 18, 2025 |
|
Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments
|
Jul 14, 2025 |
|
A Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech Landscape
|
Jun 25, 2025 |
|
Trevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic Cough
|
Jun 18, 2025 |
|
How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski
|
Jun 12, 2025 |
|
Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions
|
Jun 11, 2025 |
|
Zomedica's (OTCQB: ZOMDF) CEO Highlights Its Innovative Product Offerings and Significant Growth Opportunities in the Animal Healthcare Market
|
May 28, 2025 |
|
Enlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis Data
|
May 21, 2025 |
|
Most-Favored-Nation Drug Pricing Lacks Executive Plan
|
May 14, 2025 |
|
Current State of Biotech, Market Pressure Points, Obesity and PD-1/VEGF
|
May 08, 2025 |
|
WTR Biotech Flashcast: Neuroscience, Alzheimer’s and Biogen IOC
|
Apr 24, 2025 |
|
Annovis Bio's CEO Discusses the promise of Buntanetap in Redefining the Treatment of Alzheimer's and Parkinson's and Next Steps
|
Mar 19, 2025 |
|
Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs
|
Feb 26, 2025 |
|
OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps
|
Feb 12, 2025 |
|
Launch of WTR Biotech Spotlight Podcast with Tim Gerdeman and Do Kim
|
Feb 03, 2025 |